Explore Cabotegravir Injection and HIV Treatment Developments

Cabotegravir is an integrase strand transfer inhibitor that prevents HIV from integrating its genetic material into human cells. Its long acting formulation is administered by intramuscular injection and has a substantially longer pharmacokinetic half life than the oral formulation. For HIV treatment, injectable cabotegravir is combined with injectable rilpivirine as a complete long acting regimen. Current U.S. HIV treatment guidance describes this combination as an option for appropriately selected people with sustained viral suppression on a stable antiretroviral regimen.

How Cabotegravir Injection Is Used in HIV Care

Long acting cabotegravir has different roles depending on whether it is being used for HIV treatment or prevention. The injectable product Apretude is used for HIV pre exposure prophylaxis, while cabotegravir combined with rilpivirine in Cabenuva is used as a long acting treatment regimen for eligible people with HIV. These uses should not be confused because cabotegravir alone is not a complete HIV treatment regimen.

Important considerations for treatment include:

• Long acting cabotegravir and rilpivirine can be administered monthly or every two months in appropriate patients.
• Treatment candidates generally have sustained HIV RNA suppression and no history of treatment failure.
• Healthcare professionals assess whether there is known or suspected resistance to cabotegravir or rilpivirine.
• Oral cabotegravir can be used in certain circumstances for an oral lead in or as oral bridging when an injection is planned to be missed.
• HIV viral load and other laboratory measures remain important for monitoring treatment response.

Treatment Developments and Important Considerations

The development of long acting antiretroviral therapy represents a change from treatment approaches that rely exclusively on daily oral medication. Clinical studies have evaluated monthly and every two month cabotegravir and rilpivirine administration, with guidelines recognizing the regimen as an option for people who meet appropriate criteria.

Several factors remain important when considering long acting cabotegravir:

• Injection site reactions such as pain, swelling, induration, or nodules can occur.
• Drug interactions need to be reviewed before treatment.
• Missing scheduled injections can require an alternative oral medication strategy.
• Cabotegravir remains in the body for an extended period after administration, which is relevant when HIV infection develops after use for PrEP.
• Integrase resistance testing may be important when HIV is diagnosed following exposure to long acting cabotegravir PrEP.

Cabotegravir is therefore part of the continuing development of long acting HIV medicines. Its use requires appropriate patient selection, adherence to injection schedules, laboratory monitoring, and consideration of resistance and drug interactions. The appropriate regimen depends on individual clinical circumstances, and treatment decisions should be made with a qualified healthcare professional.